This unique, proprietary service is
exclusively available to Magnolia Medical customers as part of its
Mission to ZERO® standards change management program,
which combines evidence-based best practice techniques with the
clinically proven Steripath® family of
products.
SEATTLE,
June 27,
2024 /PRNewswire/ -- Magnolia Medical Technologies,
Inc., the inventors of the Steripath® Initial Specimen
Diversion Device® (ISDD®) and the ISDD market
to prevent false-positive sepsis test results, announced the launch
of its highly innovative, technology-enabled service solution,
Magnolia Analytics. The platform, which was developed in close
collaboration with several large U.S. hospital systems, enables
robust quantification of clinical and economic value created by
significantly reducing blood culture contamination to improve
sepsis testing accuracy.
With the launch of Magnolia Analytics, Magnolia
Medical exclusively provides hospitals and healthcare systems with
an end-to-end, software-driven solution to support sustained
achievement of the new national standard of care for blood culture
contamination performance. These new and improved standards, which
are focused on patient safety and hospital financial efficiency,
include the recent CDC guidelines – Blood Culture Contamination:
An Overview for Infection Control and Antibiotic Stewardship
Programs Working with the Clinical Laboratory.
This CDC document emphasizes eight clinically
proven mitigation steps to prevent blood culture contamination
events. The majority are based on legacy best practice techniques.
However, the addition of a new step utilizing initial specimen
diversion devices (ISDD) reflects the exhaustive clinical evidence
demonstrating the clinical efficacy of the ISDD technology category
Magnolia Medical invented. The guidelines also focus on important
public health interests associated with antibiotic stewardship and
antibiotic resistance risk that can be impacted by reducing blood
culture contamination.
Collaborating closely with hospital customers
over several years, Magnolia Medical carefully designed Magnolia
Analytics to rapidly accelerate clinical performance improvement by
streamlining workflows, data capture, and automated backend
reporting associated with sepsis diagnostics. The platform delivers
critical information to hospital department leaders as well as
quality and finance administrators quantifying the value that
Magnolia Medical's blood culture accuracy solutions deliver across
an expansive set of clinical, quality, and economic outcome
metrics.
"In response to our customer's clear unmet needs,
we developed Magnolia Analytics as a custom, exclusive solution to
support our hospitals in achieving and sustaining their blood
culture contamination rates in line with the new benchmarks
established by CDC and CLSI," said Greg
Bullington, CEO and Co-Founder of Magnolia Medical. "Truly
solving the sepsis testing accuracy problem requires a combination
of technology and technique. The continued adoption of Steripath
and Magnolia Medical's Mission to ZERO program at nearly 500
hospitals and healthcare systems to date across the U.S. speaks to
the impact of our technology solution. The addition of Magnolia
Analytics enables transparent access to performance monitoring for
hospital leadership."
The Magnolia Analytics platform can also serve as
an objective source of truth for hospitals that have adopted
devices or process interventions whose sustained performance
profiles are not supported by reliable, controlled third-party
clinical evidence. By offering Magnolia Analytics to these hospital
systems, Magnolia Medical provides the opportunity for an
independent deep-dive assessment of the true performance of these
unproven devices and interventions at the individual facility and
patient level.
With highly detailed performance data in hand,
hospital customers can objectively select clinically proven
solutions, including Steripath, that drive the strongest
improvement in patient outcomes and greatest cost reductions – all
on a sustained, measurable basis, and supported by a clinical
performance guarantee.
"Magnolia Analytics is an essential part of our
Mission to ZERO solution, providing clinicians with confidence
regarding the accuracy of blood culture results while giving our
customers peace of mind that they will continually achieve
validated, measurable, and sustained returns on their Steripath
investment," concluded Bullington.
To learn more about Magnolia Analytics, please
visit magnolia-medical.com/magnolia-analytics.
About Steripath
The Steripath® Initial Specimen
Diversion Device® platform offers the only all-in-one
devices that are clinically proven to meet the ENA, CDC, and CLSI
evidence-based best practice guidelines to reduce blood culture
contamination.1,2,3,4 To date, over 20 clinical studies,
including nine peer-reviewed publications in leading clinical
journals, have been completed supporting the clinical and cost
effectiveness of Steripath.5
Steripath and Steripath Micro have been
adopted by nearly 500 U.S. hospitals and healthcare systems to
address the problem of blood culture contamination, which can lead
to sepsis misdiagnosis resulting in unnecessary, prolonged, and
harmful antibiotic treatment, extended length of hospital stay,
false-positive CLABSIs, and wasted healthcare resources.
About Magnolia Medical Technologies
Magnolia Medical Technologies develops,
manufactures, and markets innovative blood and bodily fluid
collection devices to facilitate significant improvements in the
accuracy, consistency, and predictability of critical laboratory
tests. Magnolia Medical invented and patented the Initial Specimen
Diversion Technique® (ISDT®) and Initial
Specimen Diversion Device® (ISDD®) for blood
culture collection and contamination prevention. The company has
amassed an intellectual property portfolio, including more than 180
issued method, apparatus, and design patents with more than 50
additional patent applications pending. For more information, visit
www.magnolia-medical.com.
- Blood Culture Contamination Prevention Actions: An Overview of
Infection Control and Antibiotic Stewardship Programs Working with
the Clinical Laboratory. 2022.
- Principles and Procedures for Blood Cultures. 2nd Ed. CLSI
Guideline M47. Clinical and Laboratory Standards Institute.
2022.
- CDC National Email Update to Clinicians. Clinicians: Use this
guide to decrease blood culture contamination rates. July 2022.
- Vanhoy MA, Horigan A, Kaiser J, et al. Emergency Nurses
Association (ENA). Clinical practice guideline: prevention of blood
culture contamination. 2020.
- Date on file.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/magnolia-medical-launches-new-magnolia-analytics-service-to-streamline-data-capture-and-quantify-the-clinical--cost-effectiveness-of-preventing-sepsis-misdiagnosis-302184648.html
SOURCE Magnolia Medical Technologies